In this two-part podcast, Professor Paul G. Richardson talks about the latest clinical and research developments with novel therapies in multiple myeloma. In part one he discusses the current use of proteosome inhibitors such as bortezomib (Velcade), particularly in relation to partnering therapy and the question of class switching. In part two, Professor Richardson looks ...
Prof. Paul Richardson: current and novel therapies for multiple myeloma
16 Jan 2020
Sponsored by Janssen-Cilag Pty Ltd